TG Therapeutics Inc. (NASDAQ:TGTX) announced that the United States Patent and Trademark Office (USPTO) has issued a patent for the composition of matter of TG-1101, the Company’s novel, glycoengineered monoclonal antibody. The patent, U.S. Patent No. 9,234,045 specifically covers the composition of TG-1101, and its use for treating various forms of CD20 expressing leukemia and lymphoma, including chronic lymphocytic leukemia (CLL) and various types of non-Hodgkin’s lymphoma, including follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL).
The patent was issued to LFB SA and is exclusively licensed to TG Therapeutics pursuant to the Company’s existing license agreement with LFB SA. The issuance affords patent protection for TG-1101 in the US through July of 2029, exclusive of additional patent term extensions also available. TG-1101 is currently being studied in two Phase 3 clinical trials in patients with CLL, with additional registration directed trials in NHL expected to commence in 2016.
“We are excited to announce the issuance of the first U.S. patent for TG-1101 which affords protection through 2029. With composition of matter patents now in place for both TG-1101 and TGR-1202, and an additional later-filed patent application on the combination of TG-1101 and TGR-1202, we believe we have established a very strong intellectual property position for the two components of our proprietary ‘TG-1303’ regimen that provides a very attractive exclusivity period without the risk of generic competition for many years to come,” stated Michael S. Weiss, the Companys Executive Chairman and Interim CEO. Mr. Weiss continued, “We remain focused on continuing to strengthen our intellectual property position through the issuance of additional patents for both TG-1101 and TGR-1202 individually as well as in combination here in the US and abroad.”
TG Therapeutics Equity Analysis
TG Therapeutics Inc. (NASDAQ:TGTX) opened trading today as $8.02 and is trading in the range of 7.82-8.19 today. TG Therapeutic’s current market cap stands at $433.84 million.
Compared to other peers in the Biotechnology sector, TG Therapeutics hasn’t performed in terms of quarterly revenue growth year over year at 0.00 vs. the industry average of 0.19. TG Therapeutic’s earnings per share is currently at -1.48, which is below then the sector average of -0.56.
TG Therapeutics is currently covered by 6 Wall Street analysts. The mean target price is $26.33 according to First Call. This presents a solid upside to the current price of the equity. The Mean Recommendation sits at 1.3 which is based on 4 Strong Buy and 2 Buy ratings.
The most recent analyst actions consisted of H.C. Wainwright initiating the stock on October 27th and Brean Capital initiating coverage with an initiation rating back in April.
The current quarter EPS consensus estimate is -0.36 with revenue estimates of 30.00K. Sales are expected to drop at a 21.10% rate. TG Therapeutics reported actual earnings last quarter of -0.37 which fails to beat the -0.32 consensus estimate, a -15.60% surprise.
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. The company develops TG-1101 (ublituximab), a novel glycoengineered monoclonal antibody, which is in Phase III clinical trials and targets a epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 that is in Phase Ib/II clinical trials for relapsed/refractory non-Hodgkins lymphoma and chronic lymphocytic leukemia. It also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms; and is in a Phase I clinical trials for hematologic malignancies.